|MAS Consensus Criteria|
The project is aimed to develop a new set of classification criteria for macrophage activation syndrome (MAS) occurring in the context of systemic juvenile idiopathic arthritis.
The “Single Hub and Access point for paediatric Rheumatology in Europe” (SHARE) is a European project whose main objective is to improve the quality of care of patients suffering from Paediatric Rheumatic Diseases.
PRINTO collected samples of children with JIA newly treated with adalimumab, etanercept or tocilizumab within the project ABIRISK, funded by IMI, which has the aim to investigate antidrug antibody formation in the treatment with biopharmaceuticals
PRINTO is cross-culturally adapting and validating a questionnaire which aims to enable a multidimensional assessment of the disease status and quality of life of children with JIA: the Juvenile Arthritis Multidimensional Assessment Report (JAMAR).
|Juvenile dermatomyositis trial|
PRINTO designed the present study as a 5-year phase III single-blind, randomized clinical trial in children with newly diagnosed JDM: prednisone (PDN) versus PDN plus methotrexate, versus PDN plus Cyclosporine A…
|PRES/PRINTO/EULAR vasculitides registry|
The PReS Vasculitis Working Group, in collaboration with PRINTO and with the EULAR support designed the present registry to validate the recently developed “EULAR/PreS endorsed criteria for the classification of childhood vasculitides”.
|Genomics and Pediatric Rheumatic Diseases survey|
PRINTO designed the present survey to investigate if the PRINTO centres have families with paediatric rheumatic diseases where more cases of the same disease (e.g. JIA or JSLE or JDM etc) are present among brothers and/or sisters (affected sib pairs)
|MTX withdrawal in juvenile idiopathic arthritis|
PRINTO designed the present trial to determine if the time to discontinuation of Methotrexate (6 versus 12 months) in Juvenile Idiopathic Arthritis, after the patient has reached clinical remission, influence the time to relapse…
|Training in paediatric rheumatology for Latin America physicians|
PRINTO set up a scientific and technical collaborative network of first level research training in Paediatric Rheumatology, to support mainly Latin America and European physicians
|A web site for families of children with paediatric rheumatic diseases|
PRINTO set up a project to define to set up a web site, translated in all the language of the countries belonging to PRINTO with up-to-date consensus information on paediatric rheumatic diseases; the map of the centres…
|Disease activity and damage core sets and definition of improvement for juvenile systemic lupus erythematosus and juvenile dermatomyositis|
PRINTO set up a project to define core sets of outcome measures for disease activity and disease damage assessment and definitions of improvement, to be used in clinical trials and outcome assessment studies in children with JSLE and JDM…
|The quality of life project|
PRINTO was able to cross culturally adapt and validate 2 childhood questionnaires for the health related quality of life evaluation: the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ)…
|The methotrexate trial in intermediate versus higher dose in juvenile idiopathic arthritis|
PRINTO set up a randomized trial to compare intermediate versus higher doses of MTX in children with JIA. The trial was built on the current "standard of care"…
|Core set of outcome measures and definition of improvement for juvenile arthritis|
PRINTO first achieved goals was to define a core set of outcome measures and a definition of improvement to be used in clinical trials in children with juvenile arthritis…
|Clinical use, effect and safety of CycloSporine A (CSA) in juvenile idiopathic arthritis (JIA)|
An open-ended, phase IV post marketing surveillance study conducted among members of the Pediatric Rheumatology Collaborative Study Group (PRCSG) and of the Paediatric Rheumatology International Trials Organisation (PRINTO) to identify patients with polyarticular course JIA who had received CSA during the course of their disease.